These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 21796820)

  • 21. Sanofi Aventis grooms its ranks for biotech partnering.
    Moran N
    Nat Biotechnol; 2009 Jul; 27(7):581-2. PubMed ID: 19587645
    [No Abstract]   [Full Text] [Related]  

  • 22. Millennium and Aventis in unique pact.
    Fletcher L
    Nat Biotechnol; 2000 Aug; 18(8):817. PubMed ID: 10932140
    [No Abstract]   [Full Text] [Related]  

  • 23. The lengthening handshake.
    Osborne R
    Nat Biotechnol; 2010 Mar; 28(3):197-9. PubMed ID: 20212476
    [No Abstract]   [Full Text] [Related]  

  • 24. Row over industry link-up splits staff of Spanish lab.
    Fernandez Hermana LA
    Nature; 1994 Dec; 372(6507):586. PubMed ID: 7990935
    [No Abstract]   [Full Text] [Related]  

  • 25. Japanese firms broaden investment focus to early biotech.
    Louët S; Sipp D
    Nat Biotechnol; 2004 Aug; 22(8):931-2. PubMed ID: 15286631
    [No Abstract]   [Full Text] [Related]  

  • 26. The three pillars of bioentrepreneurship.
    Schoemaker HJ; Schoemaker AF
    Nat Biotechnol; 1998 May; 16 Suppl():13-5. PubMed ID: 9591253
    [No Abstract]   [Full Text] [Related]  

  • 27. Competitive collaboration in the pharmaceutical and biotechnology industry.
    Bingham A; Ekins S
    Drug Discov Today; 2009 Dec; 14(23-24):1079-81. PubMed ID: 19835979
    [No Abstract]   [Full Text] [Related]  

  • 28. Niche indications could drive higher valuations.
    Ransom J
    Nat Biotechnol; 2006 Dec; 24(12):1457. PubMed ID: 17160028
    [No Abstract]   [Full Text] [Related]  

  • 29. Biotechs hold their own in shifting industry.
    Mitchell P
    Nat Biotechnol; 2002 Nov; 20(11):1065-6. PubMed ID: 12410238
    [No Abstract]   [Full Text] [Related]  

  • 30. Genentech grapples with direct offer.
    Huggett B
    Nat Biotechnol; 2009 Mar; 27(3):212. PubMed ID: 19270652
    [No Abstract]   [Full Text] [Related]  

  • 31. Investing in risk management.
    Fiscus PW
    Nat Biotechnol; 1997 Jan; 15(1):88-9. PubMed ID: 9035113
    [No Abstract]   [Full Text] [Related]  

  • 32. Researchers cut loose as Pfizer and Merck shutter European sites.
    Subbaraman N
    Nat Biotechnol; 2011 Apr; 29(4):299-300. PubMed ID: 21478836
    [No Abstract]   [Full Text] [Related]  

  • 33. In search of the élite.
    Gewin V
    Nature; 2003 Dec; 426(6967):713-7. PubMed ID: 14668879
    [No Abstract]   [Full Text] [Related]  

  • 34. When times get tough.
    Jong S
    Nat Biotechnol; 2009 Mar; 27(3):226-8. PubMed ID: 19274868
    [No Abstract]   [Full Text] [Related]  

  • 35. Genzyme deal set to alter biotech landscape.
    Ledford H
    Nature; 2011 Feb; 470(7335):449. PubMed ID: 21350458
    [No Abstract]   [Full Text] [Related]  

  • 36. Biogen Idec restructures, sharpens neurology focus.
    Mitchell P
    Nat Biotechnol; 2011 Jan; 29(1):7-8. PubMed ID: 21221080
    [No Abstract]   [Full Text] [Related]  

  • 37. BIO marches to Congress with growth package in hand.
    Carey K
    Nat Biotechnol; 2011 Sep; 29(9):776-7. PubMed ID: 21904306
    [No Abstract]   [Full Text] [Related]  

  • 38. AbbVie buys last available priority voucher for $350 million.
    Morrison C
    Nat Biotechnol; 2015 Nov; 33(11):1120. PubMed ID: 26544127
    [No Abstract]   [Full Text] [Related]  

  • 39. Hatteras rounds up $90 million to lead biotech rebound in North Carolina.
    Erickson D
    Nat Biotechnol; 2015 Nov; 33(11):1121-2. PubMed ID: 26544128
    [No Abstract]   [Full Text] [Related]  

  • 40. Japan-China merger puts growth in East Asia first.
    Sipp D
    Nat Biotechnol; 2005 Aug; 23(8):907. PubMed ID: 16082348
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.